185 related articles for article (PubMed ID: 26673008)
1. FGFR1 is an adverse outcome indicator for luminal A breast cancers.
Shi YJ; Tsang JY; Ni YB; Chan SK; Chan KF; Tse GM
Oncotarget; 2016 Jan; 7(4):5063-73. PubMed ID: 26673008
[TBL] [Abstract][Full Text] [Related]
2. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor 1 protein (FGFR1) as potential prognostic and predictive marker in patients with luminal B breast cancers overexpressing human epidermal receptor 2 protein (HER2).
Amina B; Lynda AK; Sonia S; Adel B; Jelloul BH; Miloud M; Tewfik S
Indian J Pathol Microbiol; 2021; 64(2):254-260. PubMed ID: 33851617
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer.
Starska K; Forma E; Lewy-Trenda I; Stasikowska-Kanicka O; Skóra M; Bryś M
Cell Oncol (Dordr); 2018 Jun; 41(3):253-268. PubMed ID: 29299828
[TBL] [Abstract][Full Text] [Related]
5. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
Mouron S; Manso L; Caleiras E; Rodriguez-Peralto JL; Rueda OM; Caldas C; Colomer R; Quintela-Fandino M; Bueno MJ
Breast Cancer Res; 2021 Feb; 23(1):21. PubMed ID: 33579347
[TBL] [Abstract][Full Text] [Related]
6. Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer.
Inokuchi M; Murase H; Otsuki S; Kawano T; Kojima K
World J Surg Oncol; 2017 Jan; 15(1):2. PubMed ID: 28056982
[TBL] [Abstract][Full Text] [Related]
7. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
[TBL] [Abstract][Full Text] [Related]
9. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma.
Kim EK; Cho YA; Koh YW; Shin HA; Cho BC; Yoon SO
BMC Cancer; 2020 Apr; 20(1):348. PubMed ID: 32326908
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
Kim HR; Kim DJ; Kang DR; Lee JG; Lim SM; Lee CY; Rha SY; Bae MK; Lee YJ; Kim SH; Ha SJ; Soo RA; Chung KY; Kim JH; Lee JH; Shim HS; Cho BC
J Clin Oncol; 2013 Feb; 31(6):731-7. PubMed ID: 23182986
[TBL] [Abstract][Full Text] [Related]
12. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma.
Jang M; Kim E; Choi Y; Lee H; Kim Y; Kim J; Kang E; Kim SW; Kim I; Park S
Breast Cancer Res; 2012 Aug; 14(4):R115. PubMed ID: 22863309
[TBL] [Abstract][Full Text] [Related]
13. An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.
Luo J; Liu S; Leung S; Gru AA; Tao Y; Hoog J; Ho J; Davies SR; Allred DC; Salavaggione AL; Snider J; Mardis ER; Nielsen TO; Ellis MJ
J Mol Diagn; 2017 Jan; 19(1):147-161. PubMed ID: 27993329
[TBL] [Abstract][Full Text] [Related]
14. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
Park JS; Lee JS; Kim EY; Jung JY; Kim SK; Chang J; Kim DJ; Lee CY; Jung I; Kim JH; Kim HR; Moon YW; Kim HS; Cho BC; Shim HS
Lung Cancer; 2015 Jun; 88(3):325-31. PubMed ID: 25819384
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers.
Bae JM; Wen X; Kim TS; Kwak Y; Cho NY; Lee HS; Kang GH
Cancer Res Treat; 2020 Jan; 52(1):74-84. PubMed ID: 31096734
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.
Tomiguchi M; Yamamoto Y; Yamamoto-Ibusuki M; Goto-Yamaguchi L; Fujiki Y; Fujiwara S; Sueta A; Hayashi M; Takeshita T; Inao T; Iwase H
Cancer Sci; 2016 Apr; 107(4):491-8. PubMed ID: 26801869
[TBL] [Abstract][Full Text] [Related]
17. Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer.
Cheng CL; Thike AA; Tan SY; Chua PJ; Bay BH; Tan PH
Breast Cancer Res Treat; 2015 May; 151(1):99-111. PubMed ID: 25868865
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.
Tran TN; Selinger CI; Kohonen-Corish MRJ; McCaughan BC; Kennedy CW; O'Toole SA; Cooper WA
Lung Cancer; 2013 Sep; 81(3):462-467. PubMed ID: 23806793
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
Lehnen NC; von Mässenhausen A; Kalthoff H; Zhou H; Glowka T; Schütte U; Höller T; Riesner K; Boehm D; Merkelbach-Bruse S; Kirfel J; Perner S; Gütgemann I
Histopathology; 2013 Aug; 63(2):157-66. PubMed ID: 23808822
[TBL] [Abstract][Full Text] [Related]
20. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Turner N; Pearson A; Sharpe R; Lambros M; Geyer F; Lopez-Garcia MA; Natrajan R; Marchio C; Iorns E; Mackay A; Gillett C; Grigoriadis A; Tutt A; Reis-Filho JS; Ashworth A
Cancer Res; 2010 Mar; 70(5):2085-94. PubMed ID: 20179196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
